Skip to main content

Table 2 MRI signal and tumor characteristics of HCC target lesions at baseline and follow-up

From: Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib

Pat.

Dose

(mg)#

MRI-FU

Lesion

(no.)

Size

(mm)

T1

T2 fs

Necr.

[NT]/[TV] (%)

Sum

(mm)

1

-

baseline

liver

25

2

4

-

-

25

 

800

3 w.

(1)

30

4

4

↑

<25

30

 

800

8 w.

 

30

2

5

↑

<25

30

 

800

16 w.

 

34

2

5

↑

<25

34

2

-

baseline

liver

160

2

3

+

<50

170

 

400

2 w.

(2)

165

4

5

↑

<50

175

 

800

6 w.

 

160

4

3

↑

<75

172

 

400

14 w.

 

155

2

3

↑

>75

172

3

-

baseline

liver

35

2

4

-

-

35

 

800

2 w.

(4)

35

2

4

-

-

35

 

200

6 w.

 

35

2

4

-

-

35

 

200

12 w.

 

39

4

3

↑

<25

39

4

-

baseline

liver

57

3

4

+

<25

57

 

800

4 w.

(1)

57

4

5

↔

<25

57

5

-

baseline

liver

30

2

4

+

<25

30

 

800

2 w.

(1)

30

2

4

↔

<25

30

 

800

6 w.

 

31

2

5

↔

<25

31

 

400

13 w.

 

30

2

5

↔

<25

30

 

400

20 w.

 

40

2

5

↔

<25

40

6

-

baseline

liver

133

2

4

+

<25

133

 

800

3 w.

(1)

135

3

5

↑

<25

135

 

800

7 w.

 

130

2

3

↔

<25

130

7

-

baseline

liver

38

2

2

+

<25

70

 

800

2 w.

(3)

45

5

4

↑

>75

80

 

-

8 w.

 

32

3

3

↓

<50

66

 

400

16 w.

 

32

3

3

↓

<25

71

8

-

baseline

adrenal

45

3

3

+

<25

144

 

800

3 w.

(3)

45

5

4

↑

<25

144

 

400

8 w.

 

57

5

4

↑

<25

156

9

-

baseline

liver

20

2

4

-

-

119

 

800

5 w.

(3)

22

4

5

↑

>75

123

 

800

14 w.

 

20

4

5

↑

>75

119

 

800

20 w.

 

20

2

4

↑

>75

119

10

-

baseline

perit.

12

2

3

-

-

12

 

800

2 w.

(2)

12

3

5

↑

+*

12

 

800

7 w.

 

6

3

3

↔

+*

6

 

400

15 w.

 

0

-

-

-

-

0

 

400

23 w.

 

0

-

-

-

-

0

11

-

baseline

liver

10

2

4

-

-

19

 

800

3 w.

(2)

14

2

4

-

-

26

 

800

7 w.

 

17

2

4

-

-

31

 

800

15 w.

 

18

2

4

-

-

35

 

800

22 w.

 

21

2

4

-

-

38

12

-

baseline

adrenal

15

2

4

+

<25

50

 

800

4 w.

(2)

12

2

4

↑

<50

42

 

800

12 w.

 

8

2

5

↑

<50

36

 

200

19 w.

 

8

2

5

↔

<50

38

13

-

baseline

liver

38

3

4

+

<25

38

 

400

3 w.

(1)

38

3

3

↑

<25

38

 

-

7 w.

 

55

4

3

↑

<25

55

 

200

15 w.

 

39

3

3

↑

<50

39

14

-

baseline

liver

17

5

2

+

<25

70

 

800

2 w.

(2)

17

5

2

↔

<25

70

 

800

5 w.

 

17

5

2

↑

<50

70

 

200

15 w.

 

17

5

2

↔

<50

70

 

400

23 w.

 

17

5

2

↑

>75

70

15

-

baseline

bone

45

4

2

-

-

149

 

800

5 w.

(3)

55

5

4

↑

>75

176

 

800

9 w.

 

45

4

5

↔

>75

193

 

800

16 w.

 

44

4

4

↔

>75

172

 

800

21 w.

 

45

5

4

↔

>75

168

 

800

24 w.

 

50

5

3

↔

>75

163

 

800

32 w.

 

60

4

3

↔

>75

172

16

-

baseline

liver

52

4

2

+

<25

83

 

400

3 w.

(2)

52

4

2

↔

<25

83

 

-

9 w.

 

52

3

2

↔

<25

83

17

-

baseline

liver

51

1

4

+

<25

93

 

800

4 w.

(2)

57

4

5

↑

>75

107

18

-

baseline

liver

120

1

4

+

<50

120

 

800

7 w.

(1)

130

1

4

↓

<50

130

19

-

baseline

liver

151

1

4

+

<25

201

 

400

6 w.

(2)

155

4

2

↑

<50

210

 

800

18 w.

 

165

5

5

↑

>75

229

20

-

baseline

liver

15

3

3

-

-

15

 

400

2 w.

(1)

15

5

4

↑

<50

15

21

-

baseline

liver

62

2

4

-

-

88

 

400

8 w.

(2)

75

4

5

↑

<50

97

 

200

15 w.

 

75

4

5

↔

<50

97

 

200

22 w.

 

81

3

3

↔

<50

96

 

200

29 w.

 

98

5

5

↓

<50

113

  1. Abbreviations:
  2. Pat.: patient number. #Daily dose at the time point of each MRI imaging study. MRI-FU: MRI at follow-up;
  3. w.: week after therapy initiation. Lesion: location of representative analysed lesion and number of total lesions at this location. Size: size of the representative tumor lesion im mm. T1: T1-weighted image. T2fs: T2-weighted fat saturated image. Qualitative assessment of signal in relation to the signal of liver parenchyma (1 = markedly hypointense; 2 = slightly hypointense; 3 = isointense; 4 = slightly hyperintense; 5 = markedly hyperintense).
  4. PV: portal vein; perit.: peritoneal. Gd: Gadolinium-enhancement at baseline and its evolution at follow-up
  5. (↑ = increase; ↓ = decrease; ↔ = unchanged; (-) no necrosis detectable; (+) necrosis at baseline detectable). [NT]/[TV]% = percentage of necrosis volume to total tumor volume, expressed as a score with (--) no necrosis, <25%, <50%, <75%, or >75%. Sum (mm) = sum of the diameter of all detectable lesions at this location.
  6. +* = the necrotic areas could not be reliably quantified.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us